Bloom Burton & Co. Upgrades Aurinia Pharmaceuticals (AUPH) to Buy (1)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Price: $16.65 -3.25%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Bloom Burton & Co. analyst David Martin upgraded Aurinia Pharmaceuticals (NASDAQ: AUPH) from Hold (3) to Buy (1) with a price target of $21.00.
For an analyst ratings summary and ratings history on Aurinia Pharmaceuticals click here. For more ratings news on Aurinia Pharmaceuticals click here.
Shares of Aurinia Pharmaceuticals closed at $16.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Upgrades Hongfa Technology Co Ltd (600885:CH) to Buy
- Kotak Upgrades Nestle India Ltd (NEST:IN) to Add (2)
- UBS Downgrades Cembra Money Bank AG (CMBN:SW) to Sell
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
